Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice
Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosi...
Gespeichert in:
Veröffentlicht in: | American journal of orthodontics and dentofacial orthopedics 2020-05, Vol.157 (5), p.680-689 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 689 |
---|---|
container_issue | 5 |
container_start_page | 680 |
container_title | American journal of orthodontics and dentofacial orthopedics |
container_volume | 157 |
creator | Minamoto, Chisato Miyazawa, Ken Tabuchi, Masako Hirano, Miyuki Mizuno, Manami Yoshizako, Mamoru Torii, Yasuyoshi Asano, Yuichirou Sato, Takuma Kawatani, Makoto Osada, Hiroyuki Maeda, Hatsuhiko Goto, Shigemi |
description | Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA.
Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected.
Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA.
RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively.
•Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement. |
doi_str_mv | 10.1016/j.ajodo.2019.04.037 |
format | Article |
fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_miscellaneous_2397688569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0889540619309679</els_id><sourcerecordid>2397688569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</originalsourceid><addsrcrecordid>eNqNkU1r2zAYgMXoWNNuv6BQfCwMe68-bR12CKFbB4Veehe2_GpTiK1OUlLy76s0WY9lF0mH59HHI0KuKDQUqPq2bvp1GEPDgOoGRAO8_UAWFHRbq1ayM7KArtO1FKDOyUVKawDQgsEncs4Zl0IIuiAPy03G2Gcf5iq4KoeQ_1RT2OGEc66GfRVxhzFMe-vnalmVIaSM4SmGjL8x-rke0XnrD_TkLX4mH12_SfjlNF-Sxx-3j6u7-v7h56_V8r62gslc9z1o5EPrWscEKqeYHazuRzu0DLvRWrBCcCEGN2rBQUqhcXAIgrVKKckvyc1x23KRv1tM2Uw-Wdxs-hnDNhnGdau6TipdUH5EbQwpRXTmKfqpj3tDwRxCmrV5DWkOIQ0IU0IW6_p0wHaYcHxz_pUrwNcj8IxDcOlQwOIbVlJLpkFxWlaUFbr7f3rl8-uHrMJ2zkX9flSx5Nx5jOakjz6izWYM_t2XvAAddacR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2397688569</pqid></control><display><type>article</type><title>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</title><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Access via ScienceDirect (Elsevier)</source><creator>Minamoto, Chisato ; Miyazawa, Ken ; Tabuchi, Masako ; Hirano, Miyuki ; Mizuno, Manami ; Yoshizako, Mamoru ; Torii, Yasuyoshi ; Asano, Yuichirou ; Sato, Takuma ; Kawatani, Makoto ; Osada, Hiroyuki ; Maeda, Hatsuhiko ; Goto, Shigemi</creator><creatorcontrib>Minamoto, Chisato ; Miyazawa, Ken ; Tabuchi, Masako ; Hirano, Miyuki ; Mizuno, Manami ; Yoshizako, Mamoru ; Torii, Yasuyoshi ; Asano, Yuichirou ; Sato, Takuma ; Kawatani, Makoto ; Osada, Hiroyuki ; Maeda, Hatsuhiko ; Goto, Shigemi</creatorcontrib><description>Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA.
Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected.
Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA.
RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively.
•Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.</description><identifier>ISSN: 0889-5406</identifier><identifier>EISSN: 1097-6752</identifier><identifier>DOI: 10.1016/j.ajodo.2019.04.037</identifier><identifier>PMID: 32354441</identifier><language>eng</language><publisher>NEW YORK: Elsevier Inc</publisher><subject>Dentistry ; Dentistry, Oral Surgery & Medicine ; Life Sciences & Biomedicine ; Science & Technology</subject><ispartof>American journal of orthodontics and dentofacial orthopedics, 2020-05, Vol.157 (5), p.680-689</ispartof><rights>2020 American Association of Orthodontists</rights><rights>Copyright © 2020 American Association of Orthodontists. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000529063100012</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</citedby><cites>FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</cites><orcidid>0000-0002-9571-4916</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajodo.2019.04.037$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,28255,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32354441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minamoto, Chisato</creatorcontrib><creatorcontrib>Miyazawa, Ken</creatorcontrib><creatorcontrib>Tabuchi, Masako</creatorcontrib><creatorcontrib>Hirano, Miyuki</creatorcontrib><creatorcontrib>Mizuno, Manami</creatorcontrib><creatorcontrib>Yoshizako, Mamoru</creatorcontrib><creatorcontrib>Torii, Yasuyoshi</creatorcontrib><creatorcontrib>Asano, Yuichirou</creatorcontrib><creatorcontrib>Sato, Takuma</creatorcontrib><creatorcontrib>Kawatani, Makoto</creatorcontrib><creatorcontrib>Osada, Hiroyuki</creatorcontrib><creatorcontrib>Maeda, Hatsuhiko</creatorcontrib><creatorcontrib>Goto, Shigemi</creatorcontrib><title>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</title><title>American journal of orthodontics and dentofacial orthopedics</title><addtitle>AM J ORTHOD DENTOFAC</addtitle><addtitle>Am J Orthod Dentofacial Orthop</addtitle><description>Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA.
Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected.
Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA.
RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively.
•Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.</description><subject>Dentistry</subject><subject>Dentistry, Oral Surgery & Medicine</subject><subject>Life Sciences & Biomedicine</subject><subject>Science & Technology</subject><issn>0889-5406</issn><issn>1097-6752</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkU1r2zAYgMXoWNNuv6BQfCwMe68-bR12CKFbB4Veehe2_GpTiK1OUlLy76s0WY9lF0mH59HHI0KuKDQUqPq2bvp1GEPDgOoGRAO8_UAWFHRbq1ayM7KArtO1FKDOyUVKawDQgsEncs4Zl0IIuiAPy03G2Gcf5iq4KoeQ_1RT2OGEc66GfRVxhzFMe-vnalmVIaSM4SmGjL8x-rke0XnrD_TkLX4mH12_SfjlNF-Sxx-3j6u7-v7h56_V8r62gslc9z1o5EPrWscEKqeYHazuRzu0DLvRWrBCcCEGN2rBQUqhcXAIgrVKKckvyc1x23KRv1tM2Uw-Wdxs-hnDNhnGdau6TipdUH5EbQwpRXTmKfqpj3tDwRxCmrV5DWkOIQ0IU0IW6_p0wHaYcHxz_pUrwNcj8IxDcOlQwOIbVlJLpkFxWlaUFbr7f3rl8-uHrMJ2zkX9flSx5Nx5jOakjz6izWYM_t2XvAAddacR</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Minamoto, Chisato</creator><creator>Miyazawa, Ken</creator><creator>Tabuchi, Masako</creator><creator>Hirano, Miyuki</creator><creator>Mizuno, Manami</creator><creator>Yoshizako, Mamoru</creator><creator>Torii, Yasuyoshi</creator><creator>Asano, Yuichirou</creator><creator>Sato, Takuma</creator><creator>Kawatani, Makoto</creator><creator>Osada, Hiroyuki</creator><creator>Maeda, Hatsuhiko</creator><creator>Goto, Shigemi</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9571-4916</orcidid></search><sort><creationdate>202005</creationdate><title>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</title><author>Minamoto, Chisato ; Miyazawa, Ken ; Tabuchi, Masako ; Hirano, Miyuki ; Mizuno, Manami ; Yoshizako, Mamoru ; Torii, Yasuyoshi ; Asano, Yuichirou ; Sato, Takuma ; Kawatani, Makoto ; Osada, Hiroyuki ; Maeda, Hatsuhiko ; Goto, Shigemi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Dentistry</topic><topic>Dentistry, Oral Surgery & Medicine</topic><topic>Life Sciences & Biomedicine</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minamoto, Chisato</creatorcontrib><creatorcontrib>Miyazawa, Ken</creatorcontrib><creatorcontrib>Tabuchi, Masako</creatorcontrib><creatorcontrib>Hirano, Miyuki</creatorcontrib><creatorcontrib>Mizuno, Manami</creatorcontrib><creatorcontrib>Yoshizako, Mamoru</creatorcontrib><creatorcontrib>Torii, Yasuyoshi</creatorcontrib><creatorcontrib>Asano, Yuichirou</creatorcontrib><creatorcontrib>Sato, Takuma</creatorcontrib><creatorcontrib>Kawatani, Makoto</creatorcontrib><creatorcontrib>Osada, Hiroyuki</creatorcontrib><creatorcontrib>Maeda, Hatsuhiko</creatorcontrib><creatorcontrib>Goto, Shigemi</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of orthodontics and dentofacial orthopedics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minamoto, Chisato</au><au>Miyazawa, Ken</au><au>Tabuchi, Masako</au><au>Hirano, Miyuki</au><au>Mizuno, Manami</au><au>Yoshizako, Mamoru</au><au>Torii, Yasuyoshi</au><au>Asano, Yuichirou</au><au>Sato, Takuma</au><au>Kawatani, Makoto</au><au>Osada, Hiroyuki</au><au>Maeda, Hatsuhiko</au><au>Goto, Shigemi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</atitle><jtitle>American journal of orthodontics and dentofacial orthopedics</jtitle><stitle>AM J ORTHOD DENTOFAC</stitle><addtitle>Am J Orthod Dentofacial Orthop</addtitle><date>2020-05</date><risdate>2020</risdate><volume>157</volume><issue>5</issue><spage>680</spage><epage>689</epage><pages>680-689</pages><issn>0889-5406</issn><eissn>1097-6752</eissn><abstract>Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA.
Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected.
Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA.
RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively.
•Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.</abstract><cop>NEW YORK</cop><pub>Elsevier Inc</pub><pmid>32354441</pmid><doi>10.1016/j.ajodo.2019.04.037</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9571-4916</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0889-5406 |
ispartof | American journal of orthodontics and dentofacial orthopedics, 2020-05, Vol.157 (5), p.680-689 |
issn | 0889-5406 1097-6752 |
language | eng |
recordid | cdi_proquest_miscellaneous_2397688569 |
source | Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier) |
subjects | Dentistry Dentistry, Oral Surgery & Medicine Life Sciences & Biomedicine Science & Technology |
title | Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-06T11%3A59%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alteration%20of%20tooth%20movement%20by%20reveromycin%20A%20in%20osteoprotegerin-deficient%20mice&rft.jtitle=American%20journal%20of%20orthodontics%20and%20dentofacial%20orthopedics&rft.au=Minamoto,%20Chisato&rft.date=2020-05&rft.volume=157&rft.issue=5&rft.spage=680&rft.epage=689&rft.pages=680-689&rft.issn=0889-5406&rft.eissn=1097-6752&rft_id=info:doi/10.1016/j.ajodo.2019.04.037&rft_dat=%3Cproquest_webof%3E2397688569%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2397688569&rft_id=info:pmid/32354441&rft_els_id=S0889540619309679&rfr_iscdi=true |